|
|
Volumn 4, Issue 6, 2005, Pages 446-
|
|
Why big pharma needs to learn the three 'R's
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOXORUBICIN;
DRUG;
DULOXETINE;
IMATINIB;
RAPAMYCIN;
SILDENAFIL;
THALIDOMIDE;
BRAIN TUMOR;
BREAST CANCER;
CHRONIC MYELOID LEUKEMIA;
COMMERCIAL PHENOMENA;
COST CONTROL;
DRUG ACTIVITY;
DRUG APPROVAL;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG PACKAGING;
DRUG RESEARCH;
DRUG WITHDRAWAL;
ERECTILE DYSFUNCTION;
ERYTHEMA NODOSUM LEPROSUM;
HEART DISEASE;
HUMAN;
LEUKEMIA;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PATENT;
PRIORITY JOURNAL;
RESOURCE MANAGEMENT;
SARCOMA;
TECHNOLOGY;
URINE INCONTINENCE;
|
|
EID: 20844439415
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd1766 Document Type: Note |
|
Times cited : (18)
|
|
References (0)
|